Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
 - EconoTimes)
NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against PetMed Express, Inc. (NASDAQ:PETS), if they purchased the Company’s securities between May 8, 2017, and August 23, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Florida.
Get Help
PetMed Express investors should visit us at https://www.claimsfiler.com/cases/view-petmed-express-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
PetMed Express and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 23, 2017, it was revealed through a comprehensive report issued by Aurelius Value entitled “PetMed: Exploiting America’s Opioid Epidemic” that PetMed Express had targeted its products, painkillers especially addictive synthetic opiates, to opioid users through the aggressive use of Google ads and other online marketing services, potentially facilitating the abuse of opiates as “human crossover painkillers.”
On this news, the price of PetMed Express shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
